

Gunnar Birgegard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3417894/publications.pdf>

Version: 2024-02-01

74
papers

5,198
citations

201674

27
h-index

85541

71
g-index

77
all docs

77
docs citations

77
times ranked

4295
citing authors

#	ARTICLE	IF	CITATIONS
1	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. <i>Blood</i> , 2007, 110, 1092-1097.	1.4	808
2	The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. <i>European Journal of Cancer</i> , 2004, 40, 2293-2306.	2.8	749
3	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011, 29, 761-770.	1.6	724
4	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 211-222.	1.3	425
5	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. <i>Blood</i> , 2011, 118, 401-408.	1.4	280
6	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. <i>Blood</i> , 2009, 113, 4829-4833.	1.4	229
7	Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. <i>Journal of Clinical Oncology</i> , 2011, 29, 2410-2415.	1.6	215
8	Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment. <i>Oncology</i> , 2005, 68, 3-11.	1.9	156
9	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. <i>British Journal of Haematology</i> , 2010, 148, 961-963.	2.5	144
10	A phase II trial of pegylated interferon α -2b therapy for polycythemia vera and essential thrombocythemia. <i>Cancer</i> , 2006, 106, 2397-2405.	4.1	104
11	Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. <i>European Journal of Haematology</i> , 2006, 77, 378-386.	2.2	97
12	New Guidelines on Anaemia Management in Patients with Cancer: How Do These Affect Clinical Practice?. <i>Oncology</i> , 2005, 69, 17-21.	1.9	90
13	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. <i>Blood</i> , 2014, 123, 3803-3810.	1.4	79
14	Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. <i>British Journal of Haematology</i> , 1992, 81, 603-606.	2.5	65
15	Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. <i>Haematologica</i> , 2004, 89, 520-7.	3.5	64
16	Serum erythropoietin in rheumatoid arthritis and other inflammatory arthritides: relationship to anaemia and the effect of anti-inflammatory treatment. <i>British Journal of Haematology</i> , 1987, 65, 479-483.	2.5	62
17	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. <i>Haematologica</i> , 2018, 103, 51-60.	3.5	58
18	Independent Risk Factors for Anemia in Cancer Patients Receiving Chemotherapy: Results from the European Cancer Anaemia Survey. <i>Oncology</i> , 2006, 70, 34-48.	1.9	55

#	ARTICLE	IF	CITATIONS
19	A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The <sc>PROFOUND</sc> Trial. <i>Pharmacotherapy</i> , 2016, 36, 402-414.	2.6	48
20	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. <i>Haematologica</i> , 2017, 102, 85-93.	3.5	46
21	Serum Ferritin Levels in Male Blood Donors. <i>Vox Sanguinis</i> , 1978, 34, 65-70.	1.5	36
22	Change in student attitudes to medical school after the introduction of problem-based learning in spite of low ratings. <i>Medical Education</i> , 1998, 32, 46-49.	2.1	35
23	Cerebrospinal fluid ferritin in patients with cerebral infarction or bleeding. <i>Acta Neurologica Scandinavica</i> , 1980, 61, 384-392.	2.1	34
24	Serum Ferritin and Erythrocyte 2,3-DPG during Quantitated Phlebotomy and Iron Treatment. <i>Scandinavian Journal of Haematology</i> , 1977, 19, 327-333.	0.0	33
25	Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. <i>Medical Oncology</i> , 2014, 31, 302.	2.5	32
26	Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. <i>Leukemia Research</i> , 2013, 37, 162-168.	0.8	29
27	Long-term management of thrombocytosis in essential thrombocythaemia. <i>Annals of Hematology</i> , 2009, 88, 1-10.	1.8	28
28	Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. <i>Haematologica</i> , 2006, 91, 1281-2.	3.5	26
29	Caphosol® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study. <i>European Journal of Oncology Nursing</i> , 2015, 19, 50-53.	2.1	25
30	Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up. <i>Hematology</i> , 2013, 18, 8-13.	1.5	23
31	Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. <i>Haematologica</i> , 2014, 99, 679-687.	3.5	23
32	Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group. <i>European Journal of Haematology</i> , 2019, 102, 235-240.	2.2	21
33	Serum Ferritin during Inflammation A Study on Myocardial Infarction. <i>Acta Medica Scandinavica</i> , 1979, 206, 361-366.	0.0	20
34	Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. <i>Medical Oncology</i> , 2007, 24, 63-70.	2.5	19
35	Serum Ferritin in the Regulation of Iron Therapy in Blood Donors. <i>Vox Sanguinis</i> , 1980, 38, 29-35.	1.5	18
36	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. <i>Leukemia Research</i> , 2017, 63, 34-40.	0.8	18

#	ARTICLE	IF	CITATIONS
37	Managing anemia in lymphoma and multiple myeloma. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 527-539.	2.0	17
38	Serum Ferritin in Ethiopian Mothers and their Newborn Infants. Relation to Iron Intake and Socio-Economic Conditions. <i>Scandinavian Journal of Haematology</i> , 1981, 27, 247-252.	0.0	17
39	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. <i>Lancet Haematology</i> , 2021, 8, e658-e665.	4.6	17
40	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. <i>Cancer</i> , 2016, 122, 1888-1896.	4.1	16
41	Improving Awareness of the Psychosocial Needs of the Patienta Training Course for Experienced Cancer Doctors. <i>Acta Oncologica</i> , 1996, 35, 246-247.	1.8	15
42	Anagrelide Treatment in Myeloproliferative Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 260-266.	2.7	15
43	Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study. <i>Clinical Drug Investigation</i> , 2013, 33, 55-63.	2.2	15
44	Improved Care of Patients with Small Cell Lung Cancer Nutritional and Quality of Life Aspects. <i>Acta Oncologica</i> , 1992, 31, 823-831.	1.8	14
45	Advances and challenges in the management of essential thrombocythemia. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 142-156.	2.5	13
46	The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 348-355.	2.3	13
47	Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. <i>Leukemia Research</i> , 2018, 74, 105-109.	0.8	13
48	Physiological response to phlebotomies for autologous transfusion at elective hip-joint surgery. <i>European Journal of Haematology</i> , 2009, 46, 136-139.	2.2	10
49	Does anything work for anaemia in myelofibrosis?. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 175-185.	1.7	10
50	Preoperative autologous donation of 6 units of blood during rh-EPO treatment. <i>Canadian Journal of Anaesthesia</i> , 1997, 44, 1315-1318.	1.6	9
51	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISC). <i>Blood</i> , 2013, 122, 4087-4087.	1.4	9
52	Regulation of Iron Therapy by S-Ferritin Estimations in Patients on Chronic Hemodialysis. <i>Scandinavian Journal of Urology and Nephrology</i> , 1981, 15, 69-72.	1.4	7
53	Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial. <i>Blood</i> , 2013, 122, 4090-4090.	1.4	7
54	Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency. <i>Blood</i> , 2013, 122, 3439-3439.	1.4	6

#	ARTICLE	IF	CITATIONS
55	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. <i>Blood</i> , 2013, 122, 4067-4067.	1.4	6
56	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). <i>Blood</i> , 2013, 122, 4088-4088.	1.4	6
57	TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. <i>International Journal of Medical Sciences</i> , 2008, 5, 87-91.	2.5	6
58	Essential thrombocythaemia treatment options: addressing patientâ€™specific needs. <i>European Journal of Haematology</i> , 2007, 79, 27-31.	2.2	5
59	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients. <i>Blood</i> , 2010, 116, 4095-4095.	1.4	5
60	Pharmacological management of essential thrombocythemia. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1295-1306.	1.8	4
61	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2011, 118, 3839-3839.	1.4	4
62	JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling. <i>Journal of Health Economics and Outcomes Research</i> , 2020, 7, 61-70.	1.2	4
63	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. <i>Blood</i> , 2012, 120, 1726-1726.	1.4	4
64	Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment. <i>Medical Oncology</i> , 2007, 24, 318-322.	2.5	3
65	Unexpected 5 Year Survival Benefit in Patients Given Oral Cryotherapy During Conditioning for Stem Cell Transplantation. A Prospective Randomized Study. <i>Blood</i> , 2011, 118, 4559-4559.	1.4	2
66	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. <i>Blood</i> , 2012, 120, 1731-1731.	1.4	2
67	CIRCADIAN VARIATION OF GRANULOCYTE COLONY-STIMULATING FACTOR LEVELS IN MAN. <i>British Journal of Haematology</i> , 2000, 108, 661-661.	2.5	1
68	SUBCELLULAR CHARACTERIZATION OF THE TRANSFERRINâ€™TRANSFERRIN RECEPTOR AND IRON ACCUMULATING SYSTEM OF ESTABLISHED HUMAN ERYTHROID AND MONOBLASTOID TUMOUR CELL LINES. <i>Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology</i> , 1986, 94A, 245-252.	0.3	1
69	The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe. <i>HemaSphere</i> , 2019, 3, e291.	2.7	1
70	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. <i>Blood</i> , 2018, 132, 1762-1762.	1.4	1
71	New perspectives in managing myeloproliferative disorders: focus on the patient. <i>Hematological Oncology</i> , 2009, 27, 5-7.	1.7	0
72	Functional Iron Deficiency Effectively Overcome by Adjuvant IV Iron during Epoetin Treatment.. <i>Blood</i> , 2006, 108, 3725-3725.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Evaluation of beta Globin mRNA as an Early Marker of Hb Response to Epoetin Treatment.. Blood, 2006, 108, 3750-3750.	1.4	0
74	Prospective Validation of the Swedish Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Swedish) In 114 MPN Patients. Blood, 2010, 116, 5053-5053.	1.4	0